Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
1.414 Leser
Artikel bewerten:
(2)

Clarivate Plc: Clarivate Announces Winner of the 2022 Eugene Garfield Award for Innovation in Citation Analysis

The late Dr. Saeed Ul Hassan's proposal for innovation in science communications using AI wins the 2022 award

LONDON, Sept. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, has today awarded the Eugene Garfield Award for Innovation in Citation Analysis to the late Dr. Saeed Ul Hassan, senior lecturer in AI/Data Science at Manchester Metropolitan University. The award was announced at the 26th International Conference on Science, Technology and Innovation Indicators (STI 2022) by Dr. Gali Halevi, Director of the Institute for Scientific Information (ISI) at Clarivate.


Dr. Ul Hassan's winning proposal was to develop an automated, freely available online tool that would both simplify and summarize text from scientific literature, creating concise and easy-to-read abstracts. The judges felt that the proposal, titled Sustainable & Effective Science Communication: Making Science Accessible for the Public by Generating Simplified Summaries of Scientific Publications, presented an important topic that touches on the real-world challenge of making scientific papers approachable and accessible to the public.

Sadly, Dr. Ul Hassan passed away suddenly before he could be informed of his success.

Dr. Gali Halevi, Director at the Institute for Scientific Information, Clarivate said: "Dr. Ul Hassan's research and planned online tool could ensure a significant reduction in scientific misinformation especially in times of global challenges such as pandemic, climate change, sustainability and more. This is exactly the kind of innovation we look to recognise with this award, and the judges felt that it was a great example of the kind of work the ISI has pioneered.

"We were shocked and saddened to hear that Dr. Ul Hassan, a rising star in the bibliometrics community, had passed away, and our thoughts are very much with his family, friends, colleagues and students. We know he was passionate about mentoring his students, and we hope that this award will be a small part of continuing his legacy."

Prior to joining Manchester Metropolitan University, Dr. Ul Hassan spent six years at Information Technology University in Pakistan, where he was the Director of AI Lab and a faculty member. The $25,000 prize fund is being donated to ITU in recognition of his work there.

Dr. Ul Hassan published more than 50 papers in reputed international journals and conference proceedings, and was a lifetime volunteer of Pakistan Hemophilia Patient's Welfare Society and technical lead of the National Patient Registry of people with a bleeding disorder in Pakistan.

Launched in 2017, the Eugene Garfield Award for Innovation in Citation Analysis recognizes early-career scientists developing innovative approaches to citation analysis that improve how the impact of scientific research is measured. This field of study, also known as scientometrics, was pioneered by Dr. Eugene Garfield, founder of the Institute for Scientific Information.

The ISI focuses on the development of existing and new scientometric approaches. Scientometrics shapes the future of scientific discovery by helping governments, funding bodies and universities assess the impact of their work and investments, enabling them to allocate funding accordingly. It can also provide researchers with insights regarding the impact of their research, and the wider field.

Notes to editors
You can find more information about the Eugene Garfield Award for Innovation in Citation Analysis here.

About Clarivate
Clarivate is a global leader in providing solutions to accelerate the pace of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of Academia & Government, Life Sciences & Healthcare, Professional Services and Consumer Goods, Manufacturing & Technology. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.

Logo - https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

CONTACT: Rebecca Krahenbuhl, External Communications Manager, Academia & Government, newsroom@clarivate.com

© 2022 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.